

A feasibility study on Cerenkov Luminescence Imaging during prostate cancer surgery using Gallium-68 PSMA

Gepubliceerd: 04-11-2019 Laatste bijgewerkt: 18-08-2022

In this study the feasibility of the CLI will be tested to detect positive surgical margins during surgery. This will be compared to standard histopathology. When there is a good correlation between this detection, this intra-operative margin...

Ethische beoordeling	Positief advies
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Observationeel onderzoek, zonder invasieve metingen

Samenvatting

ID

NL-OMON28042

Bron

Nationaal Trial Register

Verkorte titel

CLIPPS

Aandoening

Primary prostate cancer

Ondersteuning

Primaire sponsor: This research is supported by KWF Kankerbestrijding and Technology Foundation STW, as part of their joint strategic research programme 'Technology for Oncology' (Grant number 15175).

Overige ondersteuning: This research is supported by KWF Kankerbestrijding and Technology Foundation STW, as part of their joint strategic research programme 'Technology for Oncology' (Grant number 15175).

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

The objective of this study is to assess the feasibility of 68Ga-PSMA CLI for intra-operative analysis of prostate surgical specimens.

Toelichting onderzoek

Achtergrond van het onderzoek

Prostate cancer is the second most common cancer in the world and is still the leading cancer among men in the Netherlands with over 10,000 men diagnosed each year. Surgery remains one of the primary treatment options for the disease, yet it is frequently unsuccessful with cancer left behind in a substantial number of men (11-38%). The incomplete removal of cancer during prostate cancer surgery is associated with increased likelihood of disease recurrence and poor patient outcomes. Also, these patients may undergo debilitating adjuvant therapies following surgery that have a marked impact on the patient's quality of life. Complete surgical excision is challenging, as the surgeon is unable to distinguish between cancerous and non-cancerous tissue during surgery. There is therefore an urgent medical need for surgeons to be able to visualize cancer during an operation to ensure that all of the cancer is completely removed. In this study the feasibility of Gallium-68-Prostate Specific Membrane Antigen (68Ga-PSMA) Cerenkov Luminescence Imaging (CLI) will be investigated as a technique for intraoperative analysis of prostate surgical specimens. This molecular optical technology involves imaging of Cerenkov photons, emitted from radiopharmaceuticals concentrated in cancerous tissue, using an intraoperative CLI system called LightPath®. The primary objective is to assess the feasibility of intra-operative analysis of prostate surgical specimens using 68Ga-PSMA CLI.

Study design: This study is a single-centre, prospective clinical feasibility study.

Study population: This study will include 30 high risk primary prostate cancer patients who are planned to undergo radical prostatectomy.

Intervention (if applicable): Intravenous 68Ga-PSMA injection and ex vivo CLI imaging of excised prostate specimen.

Main study parameters/endpoints: The objective of this study is to assess the feasibility of 68Ga-PSMA CLI for intra-operative analysis of prostate surgical specimens.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The subjects included in this study will receive a certain radiation exposure from the radiotracer 68Ga-PSMA that will be administered in this study. The expected radiation dose will approximately be 2 millisievert (mSV), which fall within acceptable limits.

Doel van het onderzoek

In this study the feasibility of the CLI will be tested to detect positive surgical margins during surgery. This will be compared to standard histopathology. When there is a good correlation

between this detection, this intra-operative margin assessment can guide the surgeon, and may help making the decision to operate nerve sparing or not. By providing information where the tumour is located relative to the neural-vascular bundles.

Onderzoeksopzet

NA

Onderzoeksproduct en/of interventie

Intravenous 68Ga-PSMA injection and ex vivo CLI imaging of excised prostate specimen.

Contactpersonen

Publiek

Netherlands Cancer Institute - Antoni van Leeuwenhoek
Judith olde Heuvel

0205127843

Wetenschappelijk

Netherlands Cancer Institute - Antoni van Leeuwenhoek
Judith olde Heuvel

0205127843

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

- Primary prostate cancer >18 year
- Eligible for PSMA PET scan ($PSA \geq 20$ ng/mL or $\geq cT3$ or Gleason ≥ 7)
- Tumour larger than 1.5cm on MRI.
- Signed informed consent
- Voluntary understanding
- Scheduled for radical prostatectomy surgery

- PSMA uptake on pre-operative 68Ga-PSMA PET scan

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- Usage of Indocyanine green (ICG) during surgery
- No PSMA uptake on clinical PET/CT-scan
- Subjects who have an existing medical condition that would compromise their participation in the study

Onderzoeksopzet

Opzet

Type:	Observationeel onderzoek, zonder invasieve metingen
Onderzoeksmodel:	Anders
Toewijzing:	N.v.t. / één studie arm
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland	
Status:	Werving gestart
(Verwachte) startdatum:	22-05-2019
Aantal proefpersonen:	30
Type:	Verwachte startdatum

Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

Wordt de data na het onderzoek gedeeld: Nog niet bepaald

Toelichting

This is a prospective, single-centre pilot observational study with invasive measures to assess the feasibility of 68Ga-PSMA CLI for intra-operative analysis of prostate surgical specimens.

The study will include 30 subjects with moderate to high risk prostate carcinoma, who underwent a 68Ga-PSMA PET/CT-scan and had a PSMA positive local tumor and are planned for a radical prostatectomy surgery. To be eligible for a PSMA PET/CT scan patients should have a stage \geq T3 or Gleason Score \geq 7 or PSA \geq 20ng/mL. Subjects will be approached based

on the outcomes of their clinical 68Ga-PSMA PET/CT-scan and MRI scan (tumour \geq 2cm). Subjects will be asked to participate in this study, receive written information and the informed consent form. After interim analysis, smaller tumour sizes could be included.

Ethische beoordeling

Positief advies

Datum: 04-11-2019

Soort: Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL8256
Ander register	METC AVL : METC19.0814/N18CLI

Resultaten

Samenvatting resultaten

olde Heuvel J, de Wit-van der Veen BJ, Vyas KN, Tuch DS, Grootendorst MR, Stokkel MPM, et al. Performance evaluation of Cerenkov luminescence imaging: a comparison of 68Ga with 18F. EJNMMI Phys 2019;6:17.